A commentary by lawyer and partner of BRACE Roman Shabrov has been published for the magazine “Pharmaceutical Bulletin” on what to include in a foreign economic activity contract with a Chinese manufacturer?
On March 18, 2025, Roman Shabrov, an attorney and partner at the BRACE Law Firm, spoke at the round table of the Guild of Trade and Services Enterprises of the Moscow Chamber of Commerce and Industry “Effective Ways to Deal with Violations of Contractual Obligations” with a report on the topic “Foreign Trade Contracts with Companies from China: Conditions and Options for Protection from Violations.”
A commentary by attorney at law, partner at BRACE Roman Shabrov was published in the magazine “Pharmaceutical Bulletin” on the topic of commercial policies of pharmaceutical companies: who needs them and what should be provided for in them.
A commentary by BRACE lawyer Anna Ivanova to the Pharmaceutical Herald magazine on the issue of legal regulation of donations from pharmaceutical companies has been published.
BRACE associate Anna Ivanova’s commentary was published in the article “How to Properly Design Sponsored Advertising for Pharmaceutical Companies”, published in the Pharmaceutical Bulletin magazine.
Considering the complexity of the issue of drafting and legal verification of foreign trade contracts, work on them will be carried out within the framework of a formed group with the involvement of lawyers of several specializations.
BRACE lawyer Anna Ivanova’s commentary was published in Ekaterina Pogontseva’s article “Samples Caught in the Crossfire”, published in the Pharmaceutical Bulletin magazine, on the issue of distributing medicinal product samples at specialized events for pharmaceutical and medical workers.
Among the most important changes in the regulation of the Russian pharmaceutical industry in the 2nd quarter of 2023, are the following:
:
Among the most important changes in the regulation of foreign economic activity in the 1st quarter of 2023, the following can be distinguished:
Among the most important changes in the regulation of the Russian pharmaceutical industry in the 1st quarter of 2023, the following can be distinguished:
